Filer Snapshot

Anbio Biotechnology SEC EDGAR Filings

SEC filings, ownership reports, and insider transactions for CIK 0001982708.

Entity Type

Company

Total Filings

38

Latest Filing

09 Apr 2026

Industry

In Vitro & In Vivo Diagnostic Substances

Save this filer page for the next filing cycle

Keep this page in your research queue, then return to compare new filings with prior context.

Save and revisit

Save this filer page

Create a free account to keep this page in your watchlists and return after a new SEC filing changes the record here.

Best next steps

Start with the latest filings table, then open the strongest context page for this filer.

  • Use the filings table to verify the newest submission, form type, and report period.
  • Open the deeper context page only when this filer actually has insider or ownership signal.
Source: SEC filing 20-F/A

20-F/A filed on 09 Apr 2026 for CIK 0001982708.

View Source Filing
Symbol
NNNN on Nasdaq
Business address
Friedrich Ebert Anlage 49, Frankfurt Am Main, Germany, 60308
State of incorporation
Cayman Islands
Fiscal year end
31 December

Quick Takeaways

  • Anbio Biotechnology is an SEC filer tracked under CIK 0001982708.
  • 38 filings are listed on this profile.
  • Common form coverage includes 20-F/A, 3, 20-F and more.

What Changed

  • Latest filing: 20-F/A filed on 09 Apr 2026.
  • Report period: 31 Dec 2025.

Why This Matters

  • You can quote filing dates and form types directly from the SEC record on this page.
  • Use this profile before deeper ownership or insider analysis to confirm filing history context.

Source Evidence

Source: SEC filing 20-F/A

20-F/A filed on 09 Apr 2026 for CIK 0001982708.

View Source Filing

Return Loop

Why revisit this filer page

A newly filed 20-F/A can change the filing history, ownership context, or next research path for Anbio Biotechnology.

Latest source-backed update
20-F/A filed 09 Apr 2026
Why come back
Revisit after a new SEC filing appears to compare the updated record with prior filings.
  • Latest filing on record: 20-F/A filed 09 Apr 2026.
  • Save this filer if you want a stable place to return after the next filing cycle.
  • Open the latest filing table or ownership context to verify what changed.

Filer freshness comes from SEC EDGAR submission history and related source-backed ownership or portfolio filings when available.

Latest update

What changed recently for Anbio Biotechnology

New fact period available

Latest financial period: Q4 2025. Open the source-backed page to inspect the fresh filing or facts context.

Update date

07 Apr 2026

Page type

Company facts

Latest period

Q4 2025

SEC-backed company facts were refreshed from filings filed on 07 Apr 2026.

Benchmark Context

Benchmark context for this company

Anbio Biotechnology has a source-backed company facts view where you can compare the latest reported metrics with its own recent history and with peer rankings for the same metric.

Compared with

Start on the facts page for period-to-period context, then open a metric ranking when you want to compare the same reported fact across other SEC-reporting companies.

Why this is notable

Latest financial period: Q4 2025. That gives you a fresh baseline before you compare this company with peers.

  • Latest company facts filing date: 07 Apr 2026.
  • Peer comparisons stay conservative: same metric, compatible units, latest valid company row only.
  • Open the facts page first if you want the cleanest path to verification.

Benchmark context is only shown where the app has enough comparable SEC-backed data to keep the interpretation honest.

Filer Overview

Anbio Biotechnology has filed 38 SEC EDGAR filings since 27 Dec 2023. Common forms include 20-F/A, 3, 20-F, 6-K and more.

Latest Filings

Recent SEC filings for Anbio Biotechnology with direct links to document and filing folders.

Form type Document Filing Description Filing date Reporting date File number(s)
20-F/A Open 20-F/A document | Open XBRL data View SEC filing for 20-F/A FORM 20-F/A1 09 Apr 2026 31 Dec 2025 001-42526
3 Open 3 document View SEC filing for 3 08 Apr 2026 18 Mar 2026
3 Open 3 document View SEC filing for 3 08 Apr 2026 18 Mar 2026
3 Open 3 document View SEC filing for 3 08 Apr 2026 18 Mar 2026
3 Open 3 document View SEC filing for 3 08 Apr 2026 18 Mar 2026
3 Open 3 document View SEC filing for 3 08 Apr 2026 18 Mar 2026
20-F Open 20-F document | Open XBRL data View SEC filing for 20-F FORM 20-F 07 Apr 2026 31 Dec 2025 001-42526
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 17 Feb 2026 17 Feb 2026 001-42526
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 26 Jan 2026 26 Jan 2026 001-42526
6-K Open 6-K document View SEC filing for 6-K REPORT OF FOREIGN PRIVATE ISSUER 30 Dec 2025 30 Dec 2025 001-42526
6-K Open 6-K document View SEC filing for 6-K REPORT OF FOREIGN PRIVATE ISSUER 13 Nov 2025 12 Nov 2025 001-42526
20-F Open 20-F document | Open XBRL data View SEC filing for 20-F ANNUAL REPORT 28 Apr 2025 31 Dec 2024 001-42526
6-K Open 6-K document View SEC filing for 6-K REPORT OF FOREIGN PRIVATE ISSUER 21 Feb 2025 21 Feb 2025 001-42526
424B4 Open 424B4 document View SEC filing for 424B4 PROSPECTUS 19 Feb 2025 333-284106
EFFECT Open EFFECT document View SEC filing for EFFECT 18 Feb 2025 333-284106
CERT Open CERT document View SEC filing for CERT 18 Feb 2025 001-42526
CORRESP Open CORRESP document View SEC filing for CORRESP 14 Feb 2025
CORRESP Open CORRESP document View SEC filing for CORRESP 14 Feb 2025
8-A12B Open 8-A12B document View SEC filing for 8-A12B FOR REGISTRATION OF CERTAIN CLASSES 14 Feb 2025 001-42526
F-1/A Open F-1/A document View SEC filing for F-1/A REGISTRATION STATEMENT 10 Feb 2025 333-284106
F-1/A Open F-1/A document View SEC filing for F-1/A REGISTRATION STATEMENT 24 Jan 2025 333-284106
FWP Open FWP document View SEC filing for FWP FREE WRITING PROSPECTUS 22 Jan 2025 333-284106
F-1/A Open F-1/A document View SEC filing for F-1/A REGISTRATION STATEMENT 10 Jan 2025 333-284106
F-1 Open F-1 document View SEC filing for F-1 REGISTRATION STATEMENT 31 Dec 2024 333-284106
DRSLTR Open DRSLTR document View SEC filing for DRSLTR 11 Dec 2024
DRS/A Open DRS/A document View SEC filing for DRS/A 11 Dec 2024 377-07031
UPLOAD Open UPLOAD document View SEC filing for UPLOAD 04 Dec 2024 377-07031
DRS/A Open DRS/A document View SEC filing for DRS/A 18 Nov 2024 377-07031
DRSLTR Open DRSLTR document View SEC filing for DRSLTR 01 Jul 2024
DRS/A Open DRS/A document View SEC filing for DRS/A 01 Jul 2024 377-07031
UPLOAD Open UPLOAD document View SEC filing for UPLOAD 21 Jun 2024 377-07031
DRS/A Open DRS/A document View SEC filing for DRS/A 10 Jun 2024 377-07031
DRSLTR Open DRSLTR document View SEC filing for DRSLTR 07 Jun 2024
UPLOAD Open UPLOAD document View SEC filing for UPLOAD 22 Mar 2024 377-07031
DRS/A Open DRS/A document View SEC filing for DRS/A 11 Mar 2024 377-07031
DRSLTR Open DRSLTR document View SEC filing for DRSLTR 08 Mar 2024
UPLOAD Open UPLOAD document View SEC filing for UPLOAD 23 Jan 2024 377-07031
DRS Open DRS document View SEC filing for DRS 27 Dec 2023 377-07031

About this filer

Anbio Biotechnology files with the SEC under CIK 0001982708. This page aggregates EDGAR filings and related ownership activity.

Industry: In Vitro & In Vivo Diagnostic Substances.

FAQ

What is a CIK?
A Central Index Key (CIK) is a unique identifier assigned by the SEC to each filer.
Why are some filings missing?
New filings appear as the SEC updates EDGAR, and older records can vary by availability.
How often is this page updated?
Updates follow new EDGAR submissions and periodic data refreshes.